Processing

Please wait...

PATENTSCOPE will be unavailable a few hours for maintenance reason on Tuesday 25.01.2022 at 9:00 AM CET
Settings

Settings

Goto Application

1. WO2022005101 - PHARMACEUTICAL COMPOSITION FOR PREVENTION OR TREATMENT OF FATTY LIVER DISEASE

Publication Number WO/2022/005101
Publication Date 06.01.2022
International Application No. PCT/KR2021/007940
International Filing Date 24.06.2021
IPC
A61K 31/704 2006.1
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
70Carbohydrates; Sugars; Derivatives thereof
7028Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
7034attached to a carbocyclic compound, e.g. phloridzin
704attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin, digitoxin
A61K 31/575 2006.1
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
56Compounds containing cyclopentahydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
575substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
A61P 1/16 2006.1
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
1Drugs for disorders of the alimentary tract or the digestive system
16for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
A61P 43/00 2006.1
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
43Drugs for specific purposes, not provided for in groups A61P1/-A61P41/108
A23L 33/125 2016.1
AHUMAN NECESSITIES
23FOODS OR FOODSTUFFS; THEIR TREATMENT, NOT COVERED BY OTHER CLASSES
LFOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D91; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
33Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
10using additives
125containing carbohydrate syrups; containing sugars; containing sugar alcohols; containing starch hydrolysates
Applicants
  • 연세대학교 산학협력단 INDUSTRY-ACADEMIC COOPERATION FOUNDATION, YONSEI UNIVERSITY [KR]/[KR]
  • 주식회사 큐라클 CURACLE CO., LTD. [KR]/[KR]
Inventors
  • 권영근 KWON, Young-Guen
  • 배초롱 BAE, Cho-Rong
  • 장해영 ZHANG, Haiying
  • 김명화 KIM, Myung-Hwa
  • 안구현 AHN, Koo Hyeon
Agents
  • 이원희 LEE, Won Hee
Priority Data
10-2020-008229803.07.2020KR
Publication Language Korean (ko)
Filing Language Korean (KO)
Designated States
Title
(EN) PHARMACEUTICAL COMPOSITION FOR PREVENTION OR TREATMENT OF FATTY LIVER DISEASE
(FR) COMPOSITION PHARMACEUTIQUE POUR LA PRÉVENTION OU LE TRAITEMENT DE LA STÉATOSE HÉPATIQUE
(KO) 지방간 질환의 예방 또는 치료를 위한 약학적 조성물
Abstract
(EN) The present invention provides a novel pharmaceutical composition for use in preventing or treating fatty liver disease. The pharmaceutical composition exhibits the effects of reducing fat accumulation in the liver, suppressing hepatic fibrosis, alleviating hepatitis and capillarization of liver sinusoidal endothelial cells (LSECs), etc. and as such, can be an important therapeutic agent candidate for fatty liver disease or metabolic syndromes.
(FR) La présente invention concerne une nouvelle composition pharmaceutique destinée à être utilisée pour la prévention ou le traitement de la stéatose hépatique. La composition pharmaceutique présente les effets de réduction de l'accumulation de graisses dans le foie, d'élimination de la fibrose hépatique, de soulagement de l'hépatite et de la capillarité des cellules endothéliales sinusoïdales hépatiques (LSEC), etc., et en tant que tel, peut constituer un agent thérapeutique candidat important pour la stéatose hépatique ou des syndromes métaboliques.
(KO) 본 발명은 지방간 질환의 예방 또는 치료 용도의 신규한 약학적 조성물을 제공하며, 상기 약학적 조성물은 간의 지방 축적 감소 효과, 간 섬유증 억제효과, 간염 완화 효과, 간 동모양 혈관내피세포(liver sinusoidal endothelial cells, LSECs) 모세관화 약화 효과 등을 나타내므로 지방간 질환 또는 대사 증후군의 중요한 치료제 후보가 될 수 있다.
Latest bibliographic data on file with the International Bureau